

FINANCIAL TEAR SHEET

CORPORATE PROFILE

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias.


We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

STOCK INFORMATION

IRTC (Common Stock)

| | |
|---------------------------|-----------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$84.65 |
| Change (%) | ▲ 0.31 (0.37%) |
| Volume | 7,736 |
| 52 Week Low | \$43.03 |
| Market Cap | \$2,019,832,177 |
| Rolling EPS | -1.75 |
| PE Ratio | 0 |
| Shares Outstanding | 23,948,686 |

Data as of 08/15/18 9:55 a.m. ET



RECENT NEWS

| Date | Title |
|----------|--|
| 08/01/18 | iRhythm Technologies Announces Second Quarter Financial Results |
| 07/26/18 | iRhythm Technologies to Present at the Canaccord Genuity 38th Annual Growth Conference |
| 07/18/18 | iRhythm Technologies to Report Second Quarter Financial Results on August 1, 2018 |

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

| Filing Date | Form |
|-------------|------|
| 08/07/18 | 4 |
| 08/06/18 | 4 |
| 08/06/18 | 4 |
| 08/03/18 | 4 |

Data provided by Nasdaq. Minimum 15 minutes delayed.